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AbstrACt
Objectives To investigate the incidence and determinants 
of heart failure (HF) following a myocardial infarction 
(MI) in a contemporary cohort of patients with MI using 
routinely collected primary and hospital care electronic 
health records (EHRs).
Methods Data were used from the CALIBER programme, 
linking EHRs in England from primary care, hospital 
admissions, an MI registry and mortality data. Subjects 
were eligible if they were 18 years or older, did not have 
a history of HF and survived a first MI. Factors associated 
with time to HF were examined using Cox proportional 
hazard models.
results Of the 24 479 patients with MI, 5775 (23.6%) 
developed HF during a median follow-up of 3.7 years 
(incidence rate per 1000 person-years: 63.8, 95% CI 62.2 
to 65.5). Baseline characteristics significantly associated 
with developing HF were: atrial fibrillation (HR 1.62, 95% CI 
1.51 to 1.75), age (per 10 years increase: 1.45, 1.41 to 
1.49), diabetes (1.45, 1.35 to 1.56), peripheral arterial 
disease (1.38, 1.26 to 1.51), chronic obstructive pulmonary 
disease (1.28, 1.17 to 1.40), greater socioeconomic 
deprivation (5th vs 1st quintile: 1.27, 1.13 to 1.41), ST-
segment elevation MI at presentation (1.19, 1.11 to 1.27) 
and hypertension (1.16, 1.09 to 1.23). Results were robust 
to various sensitivity analyses such as competing risk 
analysis and multiple imputation.
Conclusion In England, one in four survivors of a first 
MI develop HF within 4 years. This contemporary study 
demonstrates that patients with MI are at considerable 
risk of HF. Baseline patient characteristics associated with 
time until HF were identified, which may be used to target 
preventive strategies.
IntrOduCtIOn 
Research describing the incidence of heart 
failure (HF) following myocardial infarction 
(MI) is limited, mainly originating from the 
thrombolytic era, often using small sample 
sizes with contradictory findings, making it 
difficult to provide evidence-based medicine. 
For example, a previous UK study among 
almost 900 patients hospitalised with MI 
in 1998 found that one-fifth developed HF 
during their hospital stay and a further third 
following hospital discharge.1 More recently, 
a Swedish study found a 5-year cumulative 
risk of HF after MI of 21.8% in the calendar 
period 2004–2013.2 Further, a Danish nation-
wide cohort study reported an incidence of 
HF at 90 days following MI of 19.6% in 2009–
2010.3 Differences between these studies 
could be related to a number of factors, for 
example, change in treatment, national poli-
cies or definitions of HF, all of which poten-
tially limit the generalisability of results. We 
used a large contemporary and representative 
strengths and limitations of this study
 ► This study based on the use of linked electronic 
health records from general practitioners and 
hospital records describes the current burden of 
heart failure  (HF) in a representative sample of 
patients with a first myocardial infarction.
 ► The linkage of data from three sources (disease 
registry, primary care and hospital records) improved 
diagnostic ascertainment and accuracy in timing of 
events.
 ► Misclassification of drug exposure was likely to be 
minimal, as prescriptions issued during consultation 
are automatically recorded.
 ► Risk factor adjustment might have been incomplete 
given that information regarding baseline body mass 
index, smoking and blood pressure was missing 
for 34% to up to 70% of patients.  Due to the high 
degree of missing data on time to  revascularisation 
(88.3%), we did not explore its relation with HF 
incidence. 
 ► Stratified methods were used to account for potential 
calendar and centre effects, and competing risk 
models were used to adjust for potential competing 
effects on HF and mortality.
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sample of patients with MI based on electronic health 
records (EHRs) to (1) describe the current incidence of 
HF after MI in England, using both primary and hospital 
care data, and (2) explore patient characteristics predic-
tive of post-MI HF.
MethOds
study design
Data were used from the CALIBER dataset, which 
included linked data from (1) primary care EHRs, with 
diagnoses coded using the Read terminology (Clinical 
Practice Research Datalink, CPRD) from 226 consenting 
general practices,4 (2) hospital care administrative 
records (Hospital Episode Statistics, HES) and disease 
registry/audit records (Myocardial Ischaemia National 
Audit Project, MINAP) and (3) the mortality register 
(from UK Office for National Statistics, ONS).5
setting and participants
Patients were eligible if they were aged ≥18 years, regis-
tered in CPRD practices in England consenting to data 
linkage, with at least 1 year of up-to-standard prestudy 
follow-up (meeting CPRD practice quality standards) and 
experiencing a first MI between 1 January 1998 and 25 
March 2010. The first record of MI across the linked data 
sources was considered as the index event, and subsequent 
MI records within 30 days from the same or other sources 
were considered as representing the same event.6 Patients 
with a fatal index MI or a history of HF before their index 
MI were excluded. Patients were censored if they ceased 
to be registered at a participating general practice, at 
the date of death or the administrative censoring of the 
dataset (25 March 2010).
Variables and data sources
Study variables were derived from diagnoses recorded 
across several controlled clinical terminology and statis-
tical classification systems: Read, International Clas-
sification of Diseases (ICD)-9 or ICD-10, medication 
prescription information or the Office of Population 
Censuses and Surveys (OPCS) Classification of Inter-
ventions and Procedures-4 codes (see https:// rdrr. io/ 
rforge/ CALIBERcodelists/ man/ PRODDICT. html) with 
the EHR phenotyping algorithms published (https:// 
caliberresearch. org/ portal).5
For continuous variables, the most recent measure-
ment recorded in CPRD in the year before study entry 
was used as the baseline value. Data before study entry 
were used to determine the prognostic potential of age 
(years, using the date of birth), sex, ethnicity, social 
deprivation (Index of Multiple Deprivation, IMD score 
as recorded in ONS in quintiles), smoking, alcohol use, 
history of cardiovascular disease (CVD), previous coro-
nary revascularisation, history of diabetes, history of 
thyroid disease, history of chronic obstructive pulmonary 
disease (COPD), history of depression and history of 
non-metastatic cancer (see the CALIBER portal (https:// 
caliberresearch. org/ portal) for details). Diabetes and 
hypertension diagnosis were based on Read codes from 
primary care or ICD-10 codes from HES, both of which 
were classified using primary care consultation records 
and hospital diagnosis records. Socioeconomic status 
was based on the IMD which includes seven domains of 
deprivation (income deprivation, employment depri-
vation, health deprivation and disability, education, 
skills and training deprivation, barriers to housing and 
services and living environment deprivation and crime).7 
The index MI event was characterised using ECG findings 
(eg, ST-segment elevation myocardial infarction (STEMI) 
or non-STEMI (NSTEMI)), site of infarction, mode 
and timing of reperfusion and peak cardiac biomarkers 
(troponin I, troponin T and creatine kinase). MI was 
defined by linking all of the CALIBER data sources (eg, 
HES and CPRD) with the type of MI recorded in MINAP 
and CPRD, see for more detail https://www. caliberres-
earch. org and the appendix. Characteristics regarding 
the index MI (eg, type of revascularisation and delay from 
symptom onset to delivery of reperfusion therapy) were 
derived from MINAP. This nationwide registry is part of 
an annual audit which records over 20 key MI variables.8 
Herrett and colleagues6 validated the current approach 
and showed the necessity of linking multiple sources to 
ascertain MI (see appendix for codes used). The primary 
study outcome was the first HF event following MI, 
which was similar to MI recorded in multiple CALIBER 
data sources; echocardiographic findings and New York 
Heart Association class were unavailable. All phenotypes 
were created and validated using a robust methodology 
described elsewhere9 and have been used in previously 
published studies.10 11
statistical methods
Incidence rates (cases per 1000 person-years) and 
Kaplan-Meier cumulative incidence rates of HF were 
estimated, with Kaplan-Meier curves stratified by age 
(<50, 50–65 and ≥65 years) and type of MI. Association 
between baseline variables with the onset of HF following 
MI was explored using Cox proportional hazard models. 
The proportional hazards assumption was checked using 
Schoenfeld residuals and by non-parametric correlation 
coefficients between survival time and the parameter 
specific residuals. All models were stratified on general 
practice and calendar year periods of enrolment (1998–
2001, 2001–2004, 2004–2007 and 2007–2010). Stratified 
models were used instead of frailty models because the 
former does not make any distributional assumption. 
Models were sequentially adjusted for: (1) age and 
sex, (2) cardiovascular risk factors, (3) type of MI and 
(4) comorbidities and prescribed medication. Associa-
tions are presented as HRs with 95% CIs. Analyses were 
performed using R (V.3.3.2).12
sensitivity analyses
Due to the availability of EHR from multiple sources, 
clinical diagnoses and prescriptions were completely 
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recorded. Biomarker and lifestyle measurements such 
as smoking, body mass index (BMI) and blood pressure 
were, however, incompletely recorded (see table 1). It is 
probable that these data were preferentially recorded in 
subjects perceived to be at a higher risk for early progres-
sion of CVD. Pairwise analyses regressing a complete case 
indicator on observed variables indeed showed consider-
able dependency between recorded data and missingness 
(results not shown), violating the ‘missing completely 
at random’ assumption. This dependency was used by 
multiply imputing missing data using the mice package, 
which was implemented using 20 imputed datasets and 
pooled based on Rubin’s rules (online supplementary 
methods).13
To account for the fact that patients may have 
died before the onset of HF (eg, competing risk by 
mortality), analyses were repeated using Fine and Gray 
models.14 15 As a hypothetical example of competing 
risk, let us assume that out of 100 subjects with MI, 1 
develops HF and 99 die. In a Cox’s regression analysis, 
all 99 dead subjects would be censored (implicitly, and 
incorrectly, assuming they may develop HF later in 
time), and the hazard of HF would equal 1/1. Instead, 
a Fine and Gray model recognises that the 99 dead 
subjects could never develop HF and hence calculates 
the hazard as 1/100.
In addition to these sensitivity analyses, we performed 
a cancer-stratified and revascularisation-stratified anal-
ysis. Due to discrepancies in sample size between the 
subgroups, we decided against formal interaction testing, 
which may suffer from inflated false positive rates and 
lower power in such settings.16
results
subjects and baseline characteristics
In total, there were 52 770 patients with an index MI 
during the study period (figure 1). Excluding patients 
with a fatal index MI (n=15 104), a prior history of HF 
(n=3876), missing information on the type of MI (n=97) 
and subjects with less than 1 year of follow-up prior to 
the indexing MI event (n=9214) resulted in an analytical 
cohort of 24 479 patients. Patients were recruited from 
226 general practitioner (GP) practices, with the median 
practice enrolling 101 patients (quartile (Q1) 65 and Q3 
150). Of the included subjects, 4657 patients were STEMI 
and 19 822 patients were NSTEMI (0% missing), 15 969 
(65.2%) were men (0% missing), 4538 (42.1%) currently 
smoked (56% missing), 12 258 (50.1%) had hypertension 
(0% missing) and 3014 (12.3%) had a history of diabetes 
at baseline (0% missing). In total, 6129 (25.0%) were 
prescribed beta-blockers (0% missing) and 5039 (20.6%) 
ACE inhibitors (0% missing) prior to their indexing MI 
(table 1). The number of patients identified across the 
previously defined calendar periods was reasonably stable, 
with a minimum of 5219 subjects in the period 1998–2001 
compared with a maximum of 6838 subjects identified in 
the period 2004–2007.
Incidence
Patients contributed 90 482 person-years of follow-up, 
during a median follow-up time of 3.7 years (IQR 1.5; 
6.7), and 5775 patients (23.6%) developed HF. The crude 
incidence rate of HF following a first MI was 63.8 (95% 
CI 62.2 to 65.5) per 1000 person-years. Within the first 30 
days post-MI follow-up, 2438 (10.0%) patients developed 
HF (figure 2). From day 30 onwards, 3337 (15.8%) of 
patients with MI (event free during the first 30 days) devel-
oped HF, with 6.8% experiencing an HF event within the 
first year (figure 2). The incidence of HF during the first 
30 days of follow-up was 4.3% (102) in patients younger 
than 50 years, 6.0% (459) in 50–65 year olds and 12.9% 
(1877) in those 65 years and older, with HF incidence 
increasing proportionally as time progressed towards 10 
years (figure 3 top row). The 30-day incidence of HF was 
9.5% (1892 events) for subjects with NSTEMI and 11.7% 
(546 events) for subjects with STEMI. Excluding patients 
who experienced HF within the first 30 days showed that 
patients with STEMI had a lower incidence of HF than 
subjects with NSTEMI (figure 3 lower panels). At 57 
days, the crude cumulative risk of HF in the subjects with 
NSTEMI surpassed that of the subjects with STEMI for 
the first time (0.0151 vs 0.0147), with the curves further 
diverging at 73 days of follow-up (since indexing MI).
Over the entire follow-up, 5921 subjects died, of which 
3538 were free of HF at the time. During the first 30 days 
of follow-up, only one patient died, limiting the potential 
for competing risk by all-cause mortality. In patients who 
did not have HF after 30 days accounting for competing 
risk by all-cause mortality attenuated the cumulative 
risk to be about 15% after 10 years of follow-up (online 
supplementary data). Furthermore, the cumulative risks 
of all-cause mortality and HF converged as follow-up time 
progressed towards 10 years.
Predictors of hF after multivariable adjustments
Table 2 describes the results of the previously described 
nested Cox’s models, showing little change in estimates 
between the increasingly complex models. Focusing 
on the final model, the hazard of HF increased with 
atrial fibrillation (HR 1.62, 95% CI 1.51 to 1.75), age 
(per 10 years increase: 1.45, 1.41 to 1.49), diabetes 
(1.45, 1.35 to 1.56), peripheral arterial disease (1.38, 
1.26 to 1.51), COPD (1.28, 1.17 to 1.40), hypertension 
(1.16, 1.09 to 1.23), higher socioeconomic deprivation 
(P value for the five groups <0.001) and STEMI at presen-
tation (1.19, 1.11 to 1.27). Accounting for competing risk 
by all-cause mortality had little impact on the presented 
results (online supplementary data). After multiply 
imputing, the data models were extended to include 
smoking, BMI and systolic and diastolic blood pressure 
variables which showed BMI, male sex and smoking to 
be conditionally independent prognostic factors (online 
supplementary data). The extended model 5 was imple-
mented using imputed data and non-imputed (complete 
case) data, resulting in similar HR estimates (magnitude 
and direction). Stratifying the sample on cancer diagnosis 
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Table 1 Baseline characteristics at index MI
Patients with 
STEMI
n=4657
Patients with 
NSTEMI
n=19 822
Total of patients with 
MI
n=24 479 Unknown (%)
Follow-up time (years), median (IQR) 3.3 (1.4–5.7) 3.9 (1.5–7.1) 3.7 (1.5–6.7) 0
Mean age, years (SD) 65.7 (13.2) 68.7 (13.2) 68.1 (13.2) 0
Male sex 3311 (71.1%) 12 658 (63.9%) 15 969 (65.2%) 0
Ethnicity 4.8 
  White 3466 (76.4%) 14 288 (76.1%) 17 754 (76.2%)  
  Asian 83 (1.8%) 327 (1.7%) 410 (1.8%) 
  Black 20 (0.4%) 63 (0.3%) 83 (0.4%) 
  Other 968 (21.3%) 4085 (21.7%) 5053 (21.7%) 
Body mass index (kg/m2) 70.0
  Underweight (<18.5) 22 (1.7%) 120 (2.0%) 142 (1.9%)  
  Normal (18.5–25) 335 (25.5%) 1661 (27.4%) 1996 (27.2%) 
  Overweight (25–30) 557 (43.0%) 2431 (40.2%) 2988 (40.7%) 
  Obese (>30) 381 (29.4%) 1842 (30.4%) 2223 (30.2%)
Index of Multiple Deprivation
Most deprived quintile
892 (19.2%) 3985 (20.2%) 4877 (20%) 0.4
Risk factors before index MI
  Current smoker 1235 (51.1%) 3303 (39.5%) 4538 (42.1%) 55.9
  Excess alcohol consumption 55 (9.0%) 219 (8.1%) 274 (8.3%) 86.4
  History of atrial fibrillation 358 (7.7%) 2210 (11.1%) 2568 (10.5%) 0
  History of hypertension 2117 (45.5%) 10 141 (51.2%) 12 258 (50.1%) 0
  History of peripheral arterial disease 236 (5.1%) 1475 (7.4%) 1711 (7%) 0
Previous revascularisation 
  PCI 700 (15.0%) 2044 (10.3%) 2744 (11.2%) 0 
  CABG 126 (2.7%) 843 (4.3%) 969 (4.0%) 0
  Previous TIA 154 (3.3%) 998 (5.0%) 1152 (4.7%) 0
  Previous stroke 80 (1.7%) 410 (2.1%) 490 (2.0%) 0
  History of diabetes 538 (11.6%) 2476 (12.6%) 3014 (12.3%) 0
  History of thyroid disease 237 (5.1%) 1374 (6.9%) 1661 (6.6%) 0
  History of COPD 304 (6.5%) 1634 (8.2%) 1938 (7.9%) 0
  History of non-metastatic cancer 478 (10.3%) 2282 (11.5%) 2760 (11.3%) 0
Vital signs before admission, median (IQR)
  Systolic blood pressure, mm Hg 140 (130–153) 140 (130–154) 140 (130–154) 34.2
  Diastolic blood pressure, mm Hg 80 (74–88) 80 (71–88) 80 (72–88) 34.2
Biomarkers, median (IQR)
  Troponin I (maximum) 18.4 (3.6–50.0) 2.2 (0.3–10.0) 3.88 (0.62–21.4) 88.3
  Troponin T (maximum) 1.8 (0.60–4.8) 0.4 (0.14–1.1) 0.65 (0.18–2) 90.8
  CK (maximum) 721 (222–1631) 219 (97–648) 331 (123–1068) 79.8
Biomarkers before index MI, mean (SD)
  Haemoglobin, g/dL 14.1 (1.72) 13.6 (1.84) 13.7 (1.83) 67.1
  White cell count 8.0 (2.94) 7.9 (2.92) 7.9 (2.92) 69.1
  Neutrophil count 5.0 (2.12) 5.0 (2.40) 5.0 (2.35) 71.9
  Platelets 270 (85.2) 266 (88.0) 267 (87.5) 69.1
  Erythrocyte sedimentation rate 19.5 (18.8) 22.2 (21.6) 21.8 (21.2) 89.4
  Creatinine, µmol/L 98.5 (39.1) 102.5 (47.3) 102 (46.0) 58.7
Continued
5Gho JMIH, et al. BMJ Open 2018;8:e018331. doi:10.1136/bmjopen-2017-018331
Open Access
or history of revascularisation showed broadly similar 
results between subgroups (see online supplementary 
data, focusing on the CIs); however, precision was low due 
to the limited number of patients with a history of revas-
cularisation or cancer.
dIsCussIOn
In this large population-based study using linked EHRs, 
23.6% of patients who survived a first MI developed HF 
during a median follow-up of 3.7 years, resulting in an 
incidence rate of 64 cases per 1000 person-years. Incident 
HF was associated with increasing age, higher socioeco-
nomic deprivation, a history of diabetes, atrial fibrillation, 
peripheral arterial disease, COPD, STEMI at presenta-
tion, BMI and smoking.
A previous Canadian study, using data from the period 
1994–2000,17 found that 71% of elderly patients without 
HF at index admission developed HF within 5 years’ time 
after an MI, whereas the mortality due to MI decreased in 
the same period. The Framingham Heart Study,18 using 
data from 1990 to 1999, found a 5-year post-MI HF inci-
dence of 31.9% after MI; lower than found in the Cana-
dian study. Importantly, both studies showed a higher 
incidence of post-MI HF than our more contemporary 
English cohort. This lower HF incidence is likely due 
to continued improvements of MI treatment strategies, 
which are reflected in a decreased HF incidence over 
calendar time. For example, a 20 812 sample of patients 
with MI hospitalised in Western Australia showed that 
the overall 1-year incidence of HF after MI decreased 
from 28.1% in 1996 to 16.5% in 2007.19 This decline 
is confirmed further by a national Swedish hospital 
discharge and death registry study reporting a one-third 
decline in incidence between 1993 and 2004.20 The same 
Swedish group recently reported that this trend persists 
for the period 2004–20132 and showed improved phar-
macological treatment and early revascularisation in this 
period. During a median follow-up of 4 years, 19% of the 
patients were rehospitalised because of HF. An explana-
tion for the higher percentage in our study is probably 
Patients with 
STEMI
n=4657
Patients with 
NSTEMI
n=19 822
Total of patients with 
MI
n=24 479 Unknown (%)
 eGFR-CKD-EPI 70.4 (19.9) 66.2 (19.9) 67.0 (20.0) 60.4
 Random glucose concentration, mmol/L 7.09 (3.53) 7.26 (3.89) 7.23 (3.82) 76.5
 Total cholesterol 5.39 (1.45) 5.24 (1.28) 5.27 (1.31) 63.4
 LDL cholesterol 3.24 (1.12) 3.08 (1.10) 3.11 (1.11) 81.3
Revascularisation characteristics
 Site of infarction
 Anterior
393 (40.2%) 255 (30.7%) 648 (35.9%) 92.6
 Primary PCI 258 (19.3%) 73 (3.2%) 331 (9.2%) 85.3
 Prehospital fibrinolysis 324 (7.0%) 94 (0.5%) 418 (1.7%) 0
 Median (IQR) delay from symptom to 
reperfusion (min)
150 (98–280) 160 (101–296) 153 (99–285) 88.3
Prescribed medication before index MI
 Antiplatelet 867 (18.6%) 6979 (35.2%) 7846 (32.1%) 0
 Oral anticoagulant 67 (1.4%) 624 (3.1%) 691 (2.8%) 0
 Statin 825 (17.7%) 5297 (26.7%) 6122 (25.0%) 0
 ACE inhibitor 676 (14.5%) 4363 (22.0%) 5039 (20.6%) 0
 Angiotensin receptor blocker 220 (4.7%) 1208 (6.1%) 1428 (5.8%) 0
 Beta-blocker 766 (16.4%) 5363 (27.1%) 6129 (25.0%) 0
 Calcium channel blocker 804 (17.3%) 4621 (23.3%) 5425 (22.2%) 0
 Loop diuretic 255 (5.5%) 2188 (11.0%) 2443 (10.0%) 0
 Aldosterone antagonist 24 (0.5%) 198 (1.0%) 222 (0.9%) 0
 Digoxin 53 (1.1%) 515 (2.6%) 568 (2.3%) 0
Prehospital and inhospital fibrinolysis are not mutually exclusive.
CABG, coronary artery bypass grafting; CK, creatine kinase; COPD, chronic obstructive pulmonary disease; eGFR-CKD-EPI, estimated 
glomerular filtration rate using CKD-EPI; LDL, low-density lipoprotein; MI, myocardial infarction; NSTEMI, non-ST-segment elevation 
myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; TIA, transient ischaemic 
attack. 
Table 1 Continued 
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Figure 1 Flow chart of study population CALIBER. Cardiovascular disease research using Linked Bespoke studies and 
electronic health records. CPRD, Clinical Practice Research Datalink; HF, heart failure; MI, myocardial infarction; NSTEMI, non-
ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction.
Figure 2 Incidence of HF after index MI. Kaplan-Meier curves for crude incidence of HF after MI. Left panel: 30-day follow-up 
after index MI. Right panel: 10-year follow-up (median follow-up time was 3.7 years) in patients who survived the first 30 days 
and did not develop HF during the first 30 days (30 days event free). ‘n at risk’ represents the number of subjects at risk at a 
certain time point. ‘Cum events’ represents the cumulative number of events since the previous time points. A spike histogram 
is provided (in red) at the top of the graphs providing information on the number of events across time. HF, heart failure; MI, 
myocardial  infarction.
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the inclusion of HF diagnosis made in the GP setting 
next to hospital records decreasing misclassification of 
HF events. Future efforts are needed to harmonise these 
national data sources to compare daily care and HF epide-
miology across different countries.
Prognostic factors
Similar to the current study, Torabi et al21 reported that HF 
after MI increased steeply with age. Socioeconomic depri-
vation has been shown to be an independent predictor 
of HF development and associated with an increased 
incidence of HF in MI-free subjects.22 23 Socioeconomic 
deprivation has also been associated with more frequent 
hospital admission and higher mortality in patients with 
HF.24–26 The current study extends these observations to 
HF incidence after an MI. Furthermore, we showed that 
a history of diabetes, atrial fibrillation, peripheral arterial 
disease, COPD, STEMI at presentation, BMI and smoking 
are all independently prognostic of HF after MI. Inter-
estingly, despite the size of the collected sample, sex only 
became significantly associated with HF after accounting 
for differences in BMI and smoking. Furthermore, the 
impact of male sex (HR 1.07, 95% CI 1.01 to 1.13) was 
modest indicating relative sex equality. It is of note that 
blood pressure was not significantly associated with HF. 
However, blood pressure measurements were frequently 
missing, which (even after multiple imputation) may 
be the cause of the observed lack of association, hence 
this deserves independent exploration. In this light, it 
is important to note that the diagnosis of hypertension 
was associated with HF. Potentially, these discrepancies 
between the association of blood pressure measurement 
and hypertension diagnosis can be explained by noting 
Figure 3 Incidence of HF after index MI by group. Kaplan-Meier curves for crude incidence of HF after MI stratified by group. 
Top left panel: 30-day follow-up after index MI stratified by age group. Top right panel: 10-year follow-up (median follow-up 
time was 3.7 years) in 30-day event-free patients stratified by age group. Log-rank test of patients aged ≥65 years compared 
with patients aged 50–65 years (P<0.001). Bottom left panel: 30-day follow-up after index MI stratified by MI type. Bottom 
right panel: 10-year follow-up (median follow-up time was 3.7 years) in patients who survived the first 30 days and did not 
develop HF during the first 30 days stratified by MI type. Log-rank test of NSTEMI compared with STEMI (P<0.001). ‘n at risk’ 
represents the number of subjects at risk at a certain time point, with the cumulative number of events since the previous time 
points presented between brackets. HF, heart failure; MI, myocardial infarction; NSTEMI, non-ST-segment elevation myocardial 
infarction; STEMI, ST-segment elevation myocardial infarction. 
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that a recorded diagnosis is indicative of long-term hyper-
tensions, which may be different than a single blood pres-
sure measurement in terms of prognosis. Further, given 
that both variables were included in the same model, 
the observed difference in association may suggest that 
conditional on hypertension, blood pressure itself is only 
modestly associated to HF, if at all.
strengths and limitations
The linkage of multiple EHR sources from primary and 
hospital care allowed for the collection of a representa-
tive sample,27 which enabled us to explore the prognostic 
value of routinely collected data in primary care records 
and to detect non-hospitalised HF cases. The population 
of CPRD practices has been shown broadly representa-
tive of the UK population.4 28 In total, 226 GP practices 
consented to data linkage with HES, MINAP and ONS 
(containing 3.9% of the population of England in 2006). 
A potential limitation is that the ascertainment of cardio-
vascular outcomes was not based on clinical criteria 
(eg, validated questionnaires and properly conducted 
physical examinations), practices of medical coding will 
have changed over time and there could be subgroups of 
patients with left ventricular dysfunction without clinical 
symptoms. Calendar-dependent changes over time were 
accounted for by using time-period stratified Cox models. 
We further wish to highlight the infrequent use of percu-
taneous coronary intervention in patients with STEMI, 
which was shown to be representative of the slower 
uptake in England.29 Similarly, 32% of the patients used 
antiplatelet drugs at baseline which may be a reflection of 
non-MI CVD burden. The Kaplan-Meier plots for subtype 
of MI indicate a possible violation of the proportional 
hazard assumption for this variable. However, these plots 
represent the pairwise associations between MI subtype 
and time to HF and, as such, assume that MI subtype is 
independent of other prognostic factors, which is known 
to be false. The importance of conditioning on covari-
ates is underlined by noting the Kaplan-Meier plots indi-
cating a protective effect of STEMI versus NSTEMI, which 
was significantly reversed after correcting for covariates 
Table 2 HR for heart failure in patients following a first MI using multivariable Cox regression
Model 1
n=24 479
n events=5775
Model 2
n=24 479
n events=5775
Model 3
n=24 479
n events=5775
Model 4
n=24 479
n events=5775
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Age, per 10 years 1.51 (1.48 to 1.55) 1.49 (1.46 to 1.53) 1.46 (1.43 to 1.50) 1.45 (1.41 to 1.49)
Men 1.06 (1.00 to 1.12) 1.08 (1.02 to 1.14) 1.07 (1.01 to 1.13) 1.06 (1.00 to 1.12)
Index of Multiple 
Deprivation 
Overall  P≤0.001 Overall P≤0.001 Overall P≤0.001 
  Q1 (least deprived) Reference Reference Reference 
  Q2 1.09 (0.99 to 1.20) 1.09 (0.99 to 1.20) 1.08 (0.99 to 1.19) 
  Q3 1.20 (1.09 to 1.33) 1.20 (1.08 to 1.32) 1.18 (1.07 to 1.31) 
  Q4 1.20 (1.08 to 1.33) 1.20 (1.08 to 1.33) 1.17 (1.06 to 1.30) 
  Q5 (most deprived) 1.30 (1.16 to 1.45) 1.30 (1.16 to 1.45) 1.27 (1.13 to 1.41) 
History of hypertension 1.19 (1.12 to 1.26) 1.17 (1.10 to 1.24) 1.16 (1.09 to 1.23)
History of diabetes 1.48 (1.38 to 1.60) 1.49 (1.38 to 1.60) 1.45 (1.35 to 1.56)
History of atrial 
fibrillation
1.65 (1.53 to 1.77) 1.62 (1.51 to 1.75)
Type of MI
STEMI
1.17 (1.10 to 1.26) 1.19 (1.11 to 1.27)
History of peripheral 
arterial disease
1.38 (1.26 to 1.51)
History of COPD 1.28 (1.17 to 1.40)
Prescribed ACE inhibitor 
before MI
1.06 (0.99 to 1.13)
Prescribed angiotensin 
receptor blocker before 
MI
1.00 (0.89 to 1.11)
Prescribed beta-blocker 
before MI
0.93 (0.88 to 1.00)
All analyses presented in table 2 were performed on a complete case dataset of 24 479 subjects.
COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; Q, quintile; STEMI, ST-segment elevation myocardial infarction.
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(models 3–4). Similarly, instead of using Kaplan-Meier 
plots to assess the proportional hazard assumption of 
the crude associations, we used Schoenfeld residuals to 
explore this assumption for the conditional associations 
(multivariable model 4), which did not show any viola-
tions. Based on model 4, the absolute correlation between 
the Schoenfeld residuals and time was <0.10 (eg, for MI 
subtype, this was 0.06) indicating an absence of relevant 
interaction by time (eg, non-proportionality of hazard). 
Residual confounding due to medication use (or other 
missing/mis-specified variables) might be another poten-
tial source of bias; however, our intention was not to 
perform a causal analysis between drug prescriptions and 
time to HF. As such, it is interesting to note that despite 
the large sample size, we did not observe a significant 
association of ACE, angiotensin receptor blocker or beta-
blocker prescribed prior to the indexing MI event and 
time to HF. Relatedly, we acknowledge that we did not 
assess all potential predictors of post-MI HF, for example, 
due to the high degree of missingness, we did not explore 
the prognostic potential of time to revascularisation.30
We adhered to CPRD recommendations to obtain 
up-to-standard baseline data by excluding patients with 
less than 1 year at CPRD practice prior to index MI. Previ-
ously, Lewis and colleagues showed that 3 months after 
registration with a new practice, most patient character-
istics were updated correctly, which approximated 100% 
after 1 year of follow-up.31 Assuming that duration of the 
CPRD follow-up is independent of the relations assessed 
here, excluding such patients should not hamper general-
isability of results. Using the first MI recorded in the data-
base without a prior history of HF might have introduced 
bias due to left truncation (eg, some subjects may already 
have experienced an MI before enrolment).32 However, 
CALIBER holds longitudinal records from primary and 
hospital care, making it unlikely a large part of the patients 
were misclassified as MI free and the 1 year of follow-up 
prior to entry further decreases the likelihood of misclas-
sifying patients.31 While the current data are adequate to 
identify subjects with a first MI, the subclassification of 
patients with MI into STEMI and NSTEMI, despite recent 
improvements, is known to be error prone.33 As such, 
results for MI type need replication using higher quality 
data, in perhaps purposely designed studies. Due to our 
interest in HF occurrence after a first MI, selection bias 
(eg, index event bias) was introduced.34 This index event 
bias does not impact the descriptive or prognostic value 
of the association presented and is mostly relevant if one 
wants to develop an intervention based on the associations 
presented, which was not the aim of this study. Addition-
ally, we note that we reduced the influence of selection 
bias by accounting for dependencies between predictors. 
An important caveat of electronic healthcare records is 
that these data are predominantly focused on recording 
diagnoses and prescriptions but not on their complement 
(ie, who is not diseased or who did not receive a drug). As 
such, we have assumed that subjects without a recorded 
drug prescription or diagnoses were unexposed or free of 
(that specific) disease. Provided that electronic registra-
tion is required for a patient to fill a prescription, we can 
be fairly confident that we did not miss many prescribed 
treatments. However, it is likely that some subjects were 
misclassified as free of disease while in fact they were not. 
We’ve attempted to minimise this misclassification by 
linking data across multiple healthcare settings and data 
sources (MINAP, HES and CPRD and ONS).
A final limitation is that there is a possible delay 
between primary and hospital care records. Previous 
research has shown that MI events tend to be recorded 
in primary care after the HES or MINAP record.6 The 
lower 30-day HF incidence in patients with unclassified 
MI primarily derived from primary care could be partly 
explained because of a delay in coding. Therefore, we 
showed cumulative incidence rates in patients (alive and 
HF event free within the first 30 days) from 30 days after 
index MI to account for a delay in recording of MI in 
primary care. We were unable to differentiate between 
HF with preserved ejection fraction and HF with reduced 
ejection fraction as we had no access to detailed (echocar-
diographic) parameters to assess diastolic dysfunction. It 
is likely, however, that the majority of our patients with HF 
had developed systolic dysfunction after MI.
COnClusIOn
In this large cohort study using linked EHRs in England 
from primary and hospital care, about one in four people 
developed HF within a median of 4 years after surviving a 
first MI. Increasing age, higher socioeconomic depriva-
tion, a history of hypertension, diabetes, atrial fibrillation, 
peripheral arterial disease, COPD, smoking and STEMI 
at presentation were independent determinants of new 
onset HF following MI.
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